SciColab Ventures LLC is a company.
Key people at SciColab Ventures LLC.
SciColab Ventures LLC was founded by Michael Fenn (Founder & Principal).
SciCoLab Ventures LLC is a consulting firm supporting entrepreneurial endeavors in rapidly growing science sectors, including medical devices, biotechnology, and cannabinoids.[1][2] It operates from Cambridge, Massachusetts, with a reported revenue of around $3 million, and provides expertise across diverse areas like retail and biotech innovation.[1] While not explicitly detailed as a traditional VC firm, its involvement in biotech investor presentations suggests a focus on science-driven startups, particularly in cannabinoid pharmaceuticals and related technologies.[3]
SciCoLab Ventures LLC was incorporated as a Florida Limited Liability Company in 2017 (Document Number L17000111322).[4] A key figure is its Founder/Managing Director, who holds a BS, MS, and PhD from the University of Florida's J. Crayton Pruitt Family Department of Biomedical Engineering, bringing deep expertise in biotech and medical devices.[3] The firm's evolution centers on consulting for high-growth science sectors, with early visibility in 2019 through advisory roles in cannabinoid biotech, such as Nexien BioPharma's investor outreach.[2][3]
SciCoLab Ventures rides the wave of cannabinoid biotechnology and medical device innovation, capitalizing on greenfield opportunities in FDA-compliant drug formulations and delivery systems amid expanding legalization and therapeutic demand.[3] Its timing aligns with post-2019 market forces like cannabinoid R&D acceleration, where firms like Nexien target superior alternatives to legacy therapies (e.g., Marinol, Cesamet).[3] By offering consulting and advisory muscle, it influences the ecosystem through talent networks and expertise, aiding startups in navigating regulatory pathways and commercialization in a sector projected for multi-catalyst growth.[2][3]
SciCoLab Ventures is poised to expand its consulting footprint in biotech subsectors like cannabinoids, leveraging its founder's credentials amid ongoing R&D catalysts such as novel drug approvals and sub-licensing deals.[3] Trends like advanced cannabinoid APIs and delivery tech will shape its trajectory, potentially evolving from advisor to deeper operator in startup scaling. As science commercialization heats up, its niche expertise could amplify influence in bridging academia to market, reinforcing its role in high-potential ventures.[2][3]
Key people at SciColab Ventures LLC.
SciColab Ventures LLC was founded by Michael Fenn (Founder & Principal).
